Cumberland evaluated Caldolor injection in infants from birth to six months old. Credit: Kelly Sikkema on Unsplash.

Cumberland Pharmaceuticals has reported positive results from the trial of Caldolor (ibuprofen) Injection in children ranging from birth to six months of age.

The open-label trial, which evaluated the safety and pharmacokinetics of Caldolor, enrolled 24 newborns at four medical centres across the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study found that the therapy was well tolerated overall in this patient population, with no safety concerns reported.

Furthermore, the pharmacokinetics of Caldolor behaved similarly between infants and those greater than six months of age.

Cumberland Pharmaceuticals CEO AJ Kazimi said: “We remain committed to the ongoing development of our brands and are working to make them available to new patient populations.”

Caldolor is a FDA-approved intravenous therapy for fever. It is indicated in adults and paediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as for the reduction of fever.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US Food and Drug Administration requested a series of Phase IV studies to evaluate the therapy in paediatric patients during its new drug application (NDA) approval.

Cumberland had previously completed a pain and a fever study, leading to an expanded Caldolor label for use in children six months and older.

The company completed the last of these requirements through the new clinical study.

After finalising the full study report for submission to the FDA, it will determine whether an additional paediatric indication is available for Caldolor.